Review

Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges

Sarah K. Hakuno 1,2,†, Ellis Michiels 2,3,†, Eleonore B. Kuhlemaijer 1,*, Ilse Rooman 3,
Lukas J. A. C. Hawinkels 1,*,‡, and Marije Slingerland 4,‡

1 Department of Gastroenterology and Hepatology, Leiden University Medical Center,
2300 RC Leiden, The Netherlands; s.k.hakuno@lumc.nl (S.K.H.); e.b.kuhlemaijer@lumc.nl (E.B.K.)
2 InnoSer Belgium NV, 3590 Diepenbeek, Belgium; ellis.michiels@vub.be
3 Department of Medical and Molecular Oncology, Free University Brussels, 1090 Brussels, Belgium;
ilse.rooman@vub.be
4 Department of Medical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands;
m.slingerland@lumc.nl
* Correspondence: l.j.a.c.hawinkels@lumc.nl; Tel.: +31-71-526-6736
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Abstract: Cancers affecting the gastrointestinal system are highly prevalent and their incidence is still increasing. Among them, gastric and pancreatic cancers have a dismal prognosis (survival of 5–20%) and are defined as difficult-to-treat cancers. This reflects the urge for novel therapeutic targets and aims for personalised therapies. As a prerequisite for identifying targets and test therapeutic interventions, the development of well-established, translational and reliable preclinical research models is instrumental. This review discusses the development, advantages and limitations of both patient-derived organoids (PDO) and patient-derived xenografts (PDX) for gastric and pancreatic ductal adenocarcinoma (PDAC). First and next generation multicellular PDO/PDX models are believed to faithfully generate a patient-specific avatar in a preclinical setting, opening novel therapeutic directions for these difficult-to-treat cancers. Excitingly, future opportunities such as PDO co-cultures with immune or stromal cells, organoid-on-a-chip models and humanised PDXs are the basis of a completely new area, offering close-to-human models. These tools can be exploited to understand cancer heterogeneity, which is indispensable to pave the way towards more tumour-specific therapies and, with that, better survival for patients.

Keywords: patient-derived models; patient-derived organoids; patient-derived xenografts; gastric cancer; pancreatic cancer; multicellular models; tumour modelling; co-cultures; humanised mice; tumour microenvironment

1. Introduction

The survival of cancer patients has significantly improved during the last decade as a result of a better understanding of cancer biology and development of novel promising therapies, such as immunotherapy. Despite that, cancer incidence is still increasing, and cancer is a major cause of death worldwide. However, unfortunately, some cancer types still show high relapse and mortality rates. Gastric and pancreatic cancers, two types of gastrointestinal cancer, are known to have limited treatment options, progress quickly and result in high mortality [1]. This emphasises the need for novel and effective therapeutic interventions. Previous cancer models have mainly relied on monolayer in vitro cell cultures and subcutaneous cellular grafting in immunodeficient mice. During the last decade, major advances have been made with the development of patient-derived organoid (PDO) cultures and engraftment of freshly isolated human tumour tissues in mice (patient-derived xenografts, PDXs). While differences exist regarding costs, scalability and the
contribution of the tumour microenvironment (TME), these models benefit from a high
degree of biological concordance and stability over time. Still, a lot of work needs to be
done to completely recapitulate all elements of a human tumour in preclinical research.
Here, we will discuss advantages and limitations of first generation PDO/PDX models in
the context of two difficult-to-treat gastrointestinal cancers, with particular focus on more
recent efforts to create three-dimensional (3D) multicellular models starting from PDOs
and the development of humanised PDX mice.

2. Difficult-to-Treat Gastrointestinal Cancers

Gastric cancer and pancreatic cancer are some of the most lethal cancers known, with
both occurring at a relatively high incidence. The dismal prognosis is partly due to late
diagnosis and the limited treatment options currently available. In both of these cancers,
neoplastic cells are surrounded by a significant amount of non-epithelial/stromal cells,
such as cancer-associated fibroblasts (CAFs), infiltrating immune cells and endothelial cells
forming the tumour blood vessels, all in a dense extracellular matrix. This TME favours
tumour growth and progression and it functions as a physiological barrier, hampering
oxygen supply and the delivery of therapeutics.

2.1. Gastric Cancer

There are 1,000,000 new cases of gastric cancer (GC) annually, a substantial amount of
which occur in eastern Asia and Europe. It ranks fifth in terms of incidence and fourth in
terms of mortality globally [1]. GC is known to have poor prognosis; 5-year survival rates of
only 19–31% have been reported, resulting in approximately 769,000 deaths worldwide in
2020 [1,2], partly due to late diagnosis [3]. GC metastasizes mainly to the liver, peritoneum,
lungs, bones, and lymph system [4–6]. GC is a heterogeneous disease, hampering the
development of effective treatments [7,8]. Histologically, tumours can be classified based
on the Lauren or the more elaborate World Health Organisation (WHO) classification [9,10].
In addition to these classifications, GCs can be characterised on the molecular level [11].
Research has reported mutations in \textit{KRAS}, \textit{APC}, \textit{ARID1A}, \textit{PIK3CA}, \textit{ERBB3}, \textit{HLA-B}, \textit{SMAD4},
\textit{STK11}, \textit{PTEN}, and \textit{BMPR1A}, amongst others, with the most frequent reports of mutations
in \textit{CDH1} and \textit{TP53} [11–15]. The TME also plays a role in tumour progression, as it has been
shown that a high amount of tumour stroma is associated with worse five-year survival in
GC [16]. Curative treatment for early-stage cancer involves surgical or endoscopic tumour
resection, often in combination with (neo)adjuvant chemotherapy [17,18]. Treatment selec-
tion is currently based on the tumour stage. For most patients diagnosed with advanced
(unresectable or metastatic) disease, palliative treatment and/or best supportive care are the
only available options [17]. The use of biologicals is evolving, with anti-human epidermal
growth factor receptor 2 (HER2) therapy promising in cancers with overexpression of HER2
in first line treatment and ramucirumab in second line treatment [19–21]. Furthermore,
immuno-oncology with checkpoint inhibition and immune stimulation has evolved in the
field of GC. Preliminary data show a significant survival benefit in GC patients treated with
immunochemotherapy [22].

2.2. Pancreatic Ductal Adenocarcinoma

According to recent global cancer statistics, almost half a million people are diagnosed
worldwide with pancreatic cancer every year and numbers keep rising [1]. Pancreatic
ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer and is
known for a very poor prognosis and high mortality rates. It ranks seventh in terms of
mortality worldwide and the 5-year survival rate is <10%. Similar to GC, PDAC is known
to be a heterogeneous disease, which has therapeutic implications. As with other cancers,
the TNM classification system is used to define different PDAC stages. Histologically,
PDAC is characterised by atypical tumour glands surrounded by a prominent desmoplastic
stromal mass. Genomic analyses have identified \textit{KRAS}, \textit{TP53}, \textit{CDKN2A}, and \textit{SMAD4} to
be the most commonly occurring genetic alterations, with \textit{KRAS} having a 90% prevalence.
On a molecular level, transcriptomic analysis has revealed that PDAC can be divided into two major groups, the “classical” and “basal-like” subtypes, with the latter having the worst prognosis [23–27]. PDAC usually metastasizes to the liver, peritoneum, and to the lungs [28]. Only 15–20% of PDAC cases are suitable for surgical resection and the majority of patients usually relapse within 5 years post-surgery [29]. The standard of care for (non)-resectable patients includes (neo)-adjuvant chemotherapy regimens, but this has limited efficiency, with prolonged survival times of 6–18 months [29]. Evidence is emerging that molecular subtypes and/or the presence of certain mutations, such as $KRAS^{G12C}$, might be of clinical importance in the future to improve therapeutic responses to specific inhibitors [30]. To summarise, PDAC harbours a complex mutational landscape and malignant cells are protected by a dense stromal barrier, explaining the difficulty of successful treatment.

3. First Generation PDO/PDX Modelling

Historically, two-dimensionally (2D) grown cell lines derived from human tumour tissues have been used for cancer research for many years. Being relatively simple, stable, immortal, and inexpensive, cell-line based studies have shown significant value and have led to insights in oncologic signaling and the identification of novel therapeutic targets [31]. Regardless, extrapolating preclinical findings to the clinic has become a major challenge in drug discovery because 2D models only partly represent the in vivo situation. Not all cancer cell subclones are reflected accurately in a (clonal) cell line and, importantly, there is a lack of the TME, resulting in no 3D cell–cell interactions and/or tumour–stroma interactions [31,32]. Culture conditions are also known to propagate phenotypic features that are not necessarily representative of the in vivo situation [33]. Moving forward, inclusion of patient-derived 3D models has significantly improved the representation of the in vivo situation. Here, we review PDO and PDX to better model gastric and pancreatic cancer.

3.1. Patient-Derived Organoids (PDOs)

A major breakthrough in oncology research was the discovery of how to establish human 3D organoids from human tissues and cancers [34]. Long-term murine and human organoid cultures have been generated from stem cells by stimulation of the Wnt pathway and inhibition of the Transforming Growth Factor (TGF)-β pathway [35]. Cells obtained from surgical resections and biopsies of human tumours have been successfully used to establish PDOs with high representativeness of the original tumour on a morphological, genetic, and phenotypic level [36–38]. Due to the method of culturing, PDOs have certain advantages over other cancer models (Table 1). Compared to in vivo experiments, PDOs can be generated in small volumes and at low costs. It normally takes two weeks to one month from tissue digestion until a stable PDO culture is established [38]. Culture conditions make PDOs fit for transcriptome and high-throughput drug screening, allowing in-depth studies in development and diseases, but also offering novel possibilities for more personalised treatment [39,40]. As an important drawback, the success rate of culturing PDO is highly dependent on the tumour origin, cellularity, tissue size, amount of stroma, and whether the patient received neoadjuvant therapy or not [41]. This demands standardisation of protocols to create highly representative living biobanks for these and other cancer indications.
Table 1. Overview of the features of the various patient-derived models.

| Features                        | PDO          | PDX          | Multicellular PDO | Humanised PDX |
|---------------------------------|--------------|--------------|-------------------|---------------|
| Patient tumour recapitulation   | +            | +            | ++(+)*            | ++            |
| Presence of TME                 | –            | +            | –/+               | ++            |
| Model stability                 | ++           | ++           | ?                 | ?             |
| Establishment time              | ++           | –            | ++                | –             |
| Scalability                     | ++           | +            | ?                 | –             |
| Costs                           | low          | high         | low               | very high     |

* Upon combination of multiple cell types in one model. PDO—patient-derived organoid. PDX—patient-derived xenograft. TME—Tumour microenvironment

3.1.1. Gastric Cancer PDOs

The Clevers group at the Hubrecht Institute was the first to report the establishment of gastric organoids, in 2010. They cultured murine leucine-rich-repeat-containing G-protein coupled receptor 5 (Lgr5) gastric adult stem cells in Matrigel overlaid with standard PDO growth medium, supplemented with Wnt3a and fibroblast growth factor 10 (FGF10) [35]. In 2015, they described the generation of PDOs from human GC material [42]. GC-PDOs have been assessed multiple times for their biological resemblance and stability for prolonged cell culture. Genetic characteristics, including copy number alterations (CNA), driver mutations, and ploidy have been demonstrated to match the original tumour tissue well [38,43,44]. Heterogeneity in HER2 and fibroblast growth factor receptor 2 (FGFR2) overexpressing cells in fresh tumour tissue was shown to be retained in PDOs [44], although differences in HER2 expression between primary tumour and PDOs have been reported as well [45]. Next to genetic stability, it is important to know if therapeutic responses are reflected in organoids. In that regard, it has been noted that PDOs respond better to treatment than patients do, probably because of the absence of the tumour stroma and enzymes involved in drug metabolism [41].

GC-PDOs have already led to the discovery of potential drug targets and to the testing of potential therapeutics. MicroRNAs have been implicated in the development of cancer [46], but their role in GC development has not been confirmed yet. Two independent studies illustrated a crucial role for two specific microRNAs (miR-324-3p and miR-1265) acting as an oncogene or tumour suppressor gene in GC-PDOs [47,48]. Another study described the drug efficiency of Ethalesen, a thioredoxin reductase inhibitor, which significantly reduced GC-PDO growth [49]. The applicability of GC-PDOs for high-throughput drug screening was demonstrated in a study that tested 37 anti-cancer compounds in nine PDOs. Screening took less than two weeks per organoid, showing the feasibility of achieving reproducible results [44]. An ongoing clinical trial is comparing responses to standard of care chemotherapeutics between patients and PDOs [50]. PDOs are established from biopsies taken before and after treatment to investigate the correlation between the in vitro response and the in vivo response of patients. Evaluation is performed with both histological and omics-based analysis. With an estimated forty participants, this study will contribute to further assessing the representativeness of PDOs from GC patients.

3.1.2. PDAC PDOs

In 2015, the Clevers and Tuveson research groups were the first to establish murine- and human-derived normal and pancreatic cancer organoids [36,51]. PDOs were grown in the presence of Matrigel cultured in an intestinal growth medium, supplemented with R-SPONDIN1, a Wnt pathway modulator. Engraftment of PDAC-PDOs into immunodeficient mice resulted in the formation of neoplastic lesions that progressed into invasive and metastatic PDAC [51]. Typical PDAC driver mutations, such as KRAS and SMAD4, are maintained in PDO models, as was shown by targeted sequencing [51]. Histological and genomic stability compared to the original tumours was later confirmed in other
studies as well [52–54]. As PDAC-PDOs only represent the epithelial tumour cells, this model has been extensively exploited to study tumour biology, transcriptomics, and drug screening [52,55]. The latter study demonstrated that therapeutic responses in PDOs reliably correlated with clinical responses. This strategy allows patients to be stratified into ‘responders’ versus ‘non-responders’ to specific drugs, opening opportunities for personalised treatment. Additionally this study defined a transcriptomic chemosensitivity signature [52]. However, given the large amount of stroma observed in PDAC, the clinical translation might be challenging, and this is an important limitation of current PDO-based (therapeutic) studies.

3.2. Patient-Derived Xenografts (PDXs)

One of the disadvantages of PDOs is that they do not fully represent the clinical situation, mainly due to the lack of the tumour stroma/TME and blood flow (Table 1). To be able to evaluate this, PDX studies have been performed in which a human tumour is grown in an immunodeficient mouse. Primary (tumour) tissue, obtained via surgical resection or biopsy [56,57], is engrafted heterotopically (often subcutaneously) or orthotopically in the organ of tumour origin. Subcutaneous implantation is a relatively simple, less invasive method and growth can easily be monitored in vivo. However, heterotopic PDX tumours represent the former tumour environment less accurately and do not facilitate invasion and metastasis to a similar extent, compared to orthotopic transplantation [58]. As a drawback, orthotopic PDX is often more difficult to monitor in vivo [59]. Once PDX engraftment and growth is established, the tissue can be passed to new mice, expanding the amount of tumour tissue for subsequent analysis [60]. Several researchers describe a phenomenon of serial passages having a shorter latency, which increases the tumour take rates [56,61]. This might be related to the formation of the required mouse vasculature in the PDX tissue after the first passage [62], thereby accelerating subsequent tumour growth. Different PDX generations show a 95–100% concordance for histology and differentiation status. Research also shows high concordance of key driver mutations in PDXs and their corresponding human primary tumours [63]. Retention of the original tumour characteristics makes PDX a more accurate model to predict therapeutic responses, compared to traditional cell-line based or non-human based animal models.

Apart from the advantages, there are some challenges associated with PDX models (Table 1). Firstly, tumour growth after engraftment generally has a low efficiency. Factors that influence the success rate are tissue metabolism, ischemia time, sample size, surgical procedure, tumour type, tumour stage, metastatic properties, and mouse strain [64,65]. Another limitation is that, after engraftment of patient tissue into a mouse, the patient-derived stromal and immune cells do not proliferate [66], resulting in their replacement with murine stromal cells. These cells are fully functional, but this hampers the use of PDX when it comes to evaluation of stroma-targeted therapies. Furthermore, the long time (from months to over one year) it takes to generate the primary PDX model limits the potential of the model in various research and clinical applications, such as personalised medicine.

In summary, PDX models allow increased understanding of tumour growth and dynamic tumour- (mouse) stroma interactions that regulate invasiveness and distant metastasis. Moreover, the high histological resemblance provides new oncological insights and opens interesting diagnostic, prognostic, and therapeutic applications towards more personalised medicine for difficult-to-treat cancers. More experience needs to be gained to overcome the current limitations of PDX development in the context of GC and PDAC, which we will discuss further below.

3.2.1. Gastric Cancer PDXs

For GC, PDX models have been firmly established. Success rates for initial implantation vary between 15.1% and 34.1% [56,60,61,64,67,68]. The parameters for successful engraftment in GC were reported to be associated to tumour subtype, tumour cell percentage and degree of necrosis [60]. Other studies have reported the influence of prior
chemotherapy, patient sex, and overall procedure time on PDX success rates [56,60,68]. Molecular targets for drug therapy have been evaluated for GC-PDX, and results showed that expression of the genes FGFR2, MET and HER2 in GC PDXs is representative of the original patient tumour [56,61,68]. Transcriptomic differences between original tumours and their derived PDX models have been linked to discrepancies in the Lauren classification and tumour heterogeneity [61,68]. Although literature generally reports high representativeness of patient tumours by PDXs, it is notable that some GC-PDXs have been found to have a different histology from the original tumour, illustrating the need for more reliable PDX models.

GC-PDX models have also been successfully used for drug discovery. Comparing the chemosensitivity of GC-PDXs to the original tumour shows that 80% of the cases exhibit similar responses [68]. Another study that investigated the effects of known cancer-related drugs on 50 GC-PDX models could match drug-mediated anti-tumour effects to specific gene expression profiles [69]. GC-PDXs were confirmed to be predictive for therapy when evaluating treatment responses to an epidermal growth factor receptor (EGFR) inhibitor (cetuximab) and HER2 inhibitor (trastuzumab), which is a standard of care for patients with advanced HER2+ GC [70,71]. Other reported findings include the evaluation of potential synergistic combinations of several anti-cancer drugs, with the aim of finding effective drug combinations in a personalised manner. It is suggested that co-treatment with trastuzumab and cetuximab could be the most effective therapy for EGFR+ and HER2+ GC patients [72]. However, clinical responses to this combinational therapy remain, to our knowledge, as yet unpublished.

3.2.2. PDAC PDXs

Since 2006, PDAC PDXs have been widely used in preclinical research. Tumour tissue is engrafted subcutaneously or orthotopically in the pancreas. For orthotopic modelling, fresh primary tissue is usually implanted into the pancreatic head, resulting in fast tumour growth and lymph node invasion, but no formation of distant metastasis. Studies on PDAC PDX have reported an engraftment success rate between 20 and 80%, highly dependent on cellular viability, the presence of necrotic areas, and the amount of stromal cells [73,74]. Important concordance (90–97%) between the PDX model and the original tumour could be confirmed by the presence of important driver mutations of PDAC, such as KRAS mutations, that can be maintained for over 30 PDAC PDX generations [75,76]. Although PDX models metastasize very poorly in general, one study showed that human PDAC cells could be detected in the blood of PDAC-PDX mice, demonstrating the potential to (partially) mimic the metastatic process in PDX mice [77].

PDAC PDX models have been shown to be useful for biomarker discovery, for testing chemosensitivity, and development of novel targeted therapies [78–80]. Recently, subtype-specific transcriptional signatures of both tumour and stroma have been validated in PDAC PDX (and PDO) models. These results open a new window to develop subtype-specific and/or stroma-targeting molecules that could improve the survival of PDAC patients in the future [81,82].

4. Next Generation PDO/PDX Modelling

Irrespective of the promising PDO and PDX models that were discussed above, these models require further optimisation before broader clinical implementation becomes possible. Recent progress has been made to develop complex organotypic PDO/PDX-based models to closely mimic the complexity of a human tumour. An overview of the first and next generation patient-derived models can be seen in Figure 1.
Despite all of their advantages compared to conventional 2D cell culture, current PDO models do not fully recapitulate the complex cellular environment of a human cancer, since they lack the TME, a crucial component when investigating tumour development, progression and treatment options. Given the increasing efficacy of immunotherapy, the development of multicellular in vitro models involving infiltrating immune cells has gained interest. Adding immune cells to the PDO models was reported for the first time in the context of colorectal cancer and non-small-cell lung cancer [83]. Hereby, peripheral T-cells were added to tumour PDO cultures, resulting in the enrichment of tumour reactive T-cells that were able to specifically kill the tumour PDO [84]. As TME also contains other important elements, such as CAFs, blood vessels and neurons, in vitro modelling is currently moving forward to complex organotypic systems with close-to-human representativity.

4.1. Multicellular PDO Models

The methodology of co-cultures of murine GC organoids with immune cells has been described previously [85]. Mouse-derived normal and/or tumour GC organoids were cultured with mouse-derived dendritic cells (DCs) and cytotoxic T-cells. It was postulated that these co-cultures could eventually be used as a preclinical prediction tool to assess the efficacy of immunotherapeutics in GC patients. Similar reports are scarce in the context of PDAC, which is known as an immune-suppressed or ‘cold’ tumour. One paper investigated the depletion of myeloid-derived suppressor cells as a potential therapeutic option for PDAC patients using immune cell/PDO co-cultures. Their results confirmed the immune-suppressive role of myeloid-derived suppressor cells, and thereby could explain the limited response of immune checkpoint inhibitors in PDAC patients in clinical trials [86]. To summarise, these data demonstrate that multicellular PDO co-cultures with immune cells are a feasible method to develop more complex research models with improved similarity to human tumours.

4.1.1. PDO/Immune Cell Co-Cultures

Figure 1. Overview of first and next generation patient-derived models. PDO—patient-derived organoid. PDX—patient-derived xenograft. Figure created with BioRender.com.

4.1.2. PDO/CAF Co-Cultures

Given the fact that GC and PDAC can be composed of, respectively, 50% and 70% non epithelial/stromal cells [16,87], of which the most abundant cell type is the CAF, it would be a big step forward to add CAFs to conventional PDO cultures. In 2016, a method to co-culture GC organoids with immortalised gastric fibroblasts was reported [88]. In PDAC, co-cultures of both murine- and human-derived PDOs with CAFs were first
reported in 2017, showing an important cellular interplay that stimulates the production of desmoplastic stroma within the cultures. Interestingly, this experimental set-up also led to the identification of two distinct CAF subpopulations (iCAF and myCAF) [89], which we have currently also observed in our recently developed multicellular PDAC mini tumours (Harryvan et al., in revision). Additional work has demonstrated the feasibility of developing multicellular co-cultures of PDOs with matched patient-derived fibroblasts and/or T-cells. The authors could observe activation in a subset of fibroblasts, and found evidence for interleukin 6 (IL6)-mediated signalling between tumour cells and stroma, contributing to their survival and growth [90].

4.1.3. Organoid-on-a-Chip

To further improve PDO modelling as a bridge between in vitro and in vivo modelling, it is necessary to also add additional cell types found in the tumour microenvironment, such as immune cells, endothelial cells and pericytes, to traditional PDO culture to fully recapitulate the TME. Recent progress has been made to generate highly complex multicellular tumour models using 3D bioprinting and organ-on-a-chip platforms. This topic has been reviewed extensively elsewhere [91]. The authors conclude that the combination of organoids and organ-on-a-chip technology offer important opportunities for drug discovery, personalised medicine and regenerative medicine. With the addition of other cell types to reflect the TME more faithfully, addressing the biophysical microenvironment is also of importance. A first of its kind co-culture model made use of the “gut organoid flow chip (GOFlowChip)”, a system that allows long-term luminal flow, a critically important physiologic parameter of the human gut [92]. These authors were able to optimise the model for gastric organoids and tested the addition of DCs, resulting in a tissue chip-based co-culture model of human gastric organoids and human immune cells [93]. An important factor to consider when developing such a model is the type of extracellular matrix being used. A commercially available synthetic hydrogel (VitroGel®-ORGANOID-3; TheWell Biosciences, North Brunswick Township, NJ, USA) was used during these experiments as an alternative for Matrigel, leading to more reliable and reproducible results.

4.2. Humanised PDX Models

To overcome the current limitations of the PDX models (e.g., murine tumour stroma, no immune cells), advanced PDX models are being developed, aiming to create a more human-like animal model by introducing human immune cells into conventional PDX models. These so called “humanised” mice are generated by implanting CD34+ hematopoietic stem and precursor cells [94] into an immunodeficient mouse or a mouse with a human leukocyte antigen (HLA)-expressing thymus [95–97]. As a result, a humanised mouse will have circulating human immune cells. This innovative humanised animal model appears to be superior in terms of metastatic potential compared to immunodeficient mice [98]. This recent breakthrough provides the possibility of investigating immune infiltration, testing immuno-therapeutics and performing immune-oncology screens [66,99,100]. As a disadvantage, engrafted immune cells will often not be HLA compatible with the implanted PDX, hampering full clinical representativeness. Furthermore, they come at high costs and with demanding logistics. Still, these models are a valuable addition to current patient-derived models. Below we discuss the current studies on humanised PDX for GC and PDAC.

In general, humanised PDX models to study GC and PDAC are still limited at the moment. Probably, the establishment and use of such models will increase in the next decade and will offer significant preclinical value, especially in terms of immunotherapeutic approaches. Humanised mice for GC-PDXs have been described previously [101]. Mice that were pre-infused with human peripheral blood mononuclear cells (PBMCs) were implanted subcutaneously with gastric tumour tissue from the same patient. Next, the authors found that treatment with anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab) significantly decreased tumour growth, affirming the clinical relevance of these humanised PDX models.
To our knowledge, only one study has been published in which PDAC tissue could be successfully engrafted in immunocompetent mice. Upon tumour growth, infiltration of human-derived natural killer cells was observed, which inhibited PDAC tumour growth by specifically targeting cancer stem cells [102]. Considering that PDAC is a stroma-rich tumour with immunosuppressive features, current clinical approved immunotherapeutics have mostly failed in clinical trials for PDAC. Interestingly, transcriptomics on PDAC PDXs suggest a subgroup of PDAC patients with an immune enriched tumour, highlighting the clinical importance of further exploring humanised PDX models, also in the context of PDAC [25].

4.3. MiniPDX Models

Ideally, therapeutic decision making in the clinic would be based on the response of preclinical tumour models. This is not yet feasible, given the long latency before a PDX is established. To overcome this limitation, the “MiniPDX” was developed [103]. In this model, tumour cells were put into hollow fibre capsules before transplantation into an animal. This new technique significantly decreases engraftment time to 7 days. Recently, the feasibility of MiniPDX-guided treatment decisions was assessed in GC patients with liver metastases [104]. The authors reported that the given chemotherapy regimen, based on the response in MiniPDXs, was promising to prolong survival. Another study showed that in a herceptin-resistant GC patient, the MiniPDX method was relevant for drug screening, since it resulted in a clinical benefit for this particular case [105]. Larger clinical cohorts are needed to further confirm these findings.

5. Future Perspectives

The majority of novel targeted therapies that are being developed for GC and PDAC often fail during clinical evaluation, at least partially due to the fact that current models are not sufficiently reflective of the patient. Taking into account the low prevalence of targetable molecules or mutations [106], there is a great need for the development of innovative research models that are very similar to the human tumour. Multicellular PDO co-cultures and humanised PDX models are presented as next generation 3D methods to include important elements of the TME, increasing model representativeness to the in vivo situation.

Considering the high correlation between the original tumour and the first generation PDO/PDX models, these tools are not only valuable for preclinical research and disease modelling but also offer an assessment of drug sensitivity, paving the way towards personalised medicine in the clinic. Preliminary results of the HOPE trial recently tested the feasibility of generating PDO from PDAC patients within a relevant timeframe in a clinical setting. This proof-of-concept study highlighted the important potential of PDOs to display a patient-specific avatar, enabling accurate patient selection when targeted therapies are considered [107]. In parallel, PDX models have proven their utility to assess drug sensitivity profiles and to identify potentially new actionable targets [82]. To illustrate this, the recently presented “Gempred”, a predictive gene signature to gemcitabine, has been shown to be useful in a clinical setting [82]. Table 1 illustrates differences between first and next generation PDO/PDX models, reporting increased tumour representativeness by including TME in the next generation models. Since this type of modelling is a completely new area, more studies are necessary to evaluate the model’s stability, scalability and (clinical) applicability.

We expect that moving on to multicellular PDO co-cultures, humanised PDXs and complex organotypic systems will lead to the generation of close-to-human models. Such models will undoubtedly offer significant insights into tumour heterogeneity, which is of underestimated value, especially when it comes to difficult-to-treat gastrointestinal cancers such as GC and PDAC. We therefore believe that it is crucial that the cancer research field prioritises the firm establishment of these next generation models and implementation in (all) cancer research. Although there are promising aspects, we have to account for some
important considerations associated with the development and use of proposed advanced 3D models. Collecting different tissue types and cell populations from the same patient demands an intensive collaboration between research labs and clinicians. Moreover, ethical concerns are increasing because these models are still based on non-human elements (mice and Matrigel), hampering clinical translation. To conclude, current developments and findings are encouraging, suggesting that they will eventually generate superior close-to-human preclinical models, allowing complete understanding of tumour biology and thereby facilitating and accelerating drug discovery and development in oncology.

**Author Contributions:** Conceptualization, L.J.A.C.H. and M.S.; writing—original draft preparation, E.B.K., E.M., S.K.H.; writing—review and editing, E.M., S.K.H., I.R., L.J.A.C.H. and M.S.; visualization, E.M. and S.K.H.; supervision, I.R., L.J.A.C.H. and M.S.; funding acquisition, I.R., L.J.A.C.H. and M.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** Studies in our labs are supported by a research grant from the Flanders Agency for Research and Innovation (VLAIO) grant (HBC.2018.2002).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors would like to thank Tulya Kavaklioglu and Casey Kilmore for their contribution to the design of Figure 1.

**Conflicts of Interest:** Both Sarah K. Hakuno and Ellis Michiels are employed by InnoSer België NV at the time of submission of this review article. Lukas J.A.C. Hawinkels and Marije Slingerland are on the scientific advisory board of InnoSer België NV.

**References**

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 2021, 71, 209–249. [CrossRef] [PubMed]
2. Rawla, P.; Barsouk, A. Epidemiology of gastric cancer: Global trends, risk factors and prevention. *Prz. Gastroenterol.* 2019, 14, 26–38. [CrossRef]
3. Liu, X.; Meltzer, S.J. Gastric Cancer in the Era of Precision Medicine. *Cell. Mol. Gastroenterol. Hepatol.* 2017, 3, 348–358. [CrossRef] [PubMed]
4. Mashino, K.; Sadanaga, N.; Yamaguchi, H.; Tanaka, F.; Ohta, M.; Shibuta, K.; Inoue, H.; Mori, M. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. *Cancer Res.* 2002, 62, 2937–2941.
5. Riikimaki, M.; Hemminki, A.; Sundquist, K.; Sundquist, J.; Hemminki, K. Metastatic spread in patients with gastric cancer. *Oncotarget* 2016, 7, 52307–52316. [CrossRef] [PubMed]
6. Zhang, H.; Deng, T.; Liu, R.; Bai, M.; Zhou, L.; Wang, X.; Li, S.; Wang, X.; Yang, H.; Li, J.; et al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. *Nat. Commun.* 2017, 8, 15016. [CrossRef]
7. Gullo, I.; Carneiro, F.; Oliveira, C.; Almeida, G.M. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. *Pathobiology* 2018, 85, 50–63. [CrossRef]
8. Ho, S.W.T.; Tan, P. Dissection of gastric cancer heterogeneity for precision oncology. *Cancer Sci.* 2019, 110, 3405–3414. [CrossRef]
9. Laurén, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and so-called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. *Acta Pathol. Microbiol. Scand.* 1965, 64, 31–49. [CrossRef] [PubMed]
10. WHO Classification of Tumours Editorial Board. *Digestive System Tumours*, 5th ed.; World Health Organization: Geneva, Switzerland, 2019; Volume 1.
11. Bass, A.J.; Thorsson, V.; Shmulevich, I.; Reynolds, S.M.; Miller, M.; Bernard, B.; Hinoue, T.; Laird, P.W.; Curtis, C.; The Cancer Genome Atlas Research Network; et al. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014, 513, 202–209. Available online: https://www.nature.com/articles/nature13480#supplementary-information (accessed on 3 February 2022).
12. Ito, T.; Matoba, R.; Maekawa, H.; Sakurada, M.; Kushida, T.; Orita, H.; Wada, R.; Sato, K. Detection of gene mutations in gastric cancer tissues using a commercial sequencing panel. *Mol. Clin. Oncol.* 2019, 11, 455–460. [CrossRef] [PubMed]
13. Jang, B.-G.; Kim, W.H. Molecular Pathology of Gastric Carcinoma. *Pathobiology* 2011, 78, 302–310. [CrossRef]
14. Nemtsova, M.V.; Kalinkin, A.I.; Kuznetsova, E.B.; Bure, I.V.; Alekseeva, E.A.; Bykov, I.I.; Khorobykh, T.V.; Mikhailenko, D.S.; Tanas, A.S.; Kutsev, S.I.; et al. Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing. *Sci. Rep.* 2020, 10, 504. [CrossRef] [PubMed]
38. Gao, M.; Lin, M.; Rao, M.; Thompson, H.; Hirai, K.; Choi, M.; Georgakis, G.V.; Sasson, A.R.; Bucobo, J.C.; Tzimas, D.; et al. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. *Ann. Surg. Oncol.* **2018**, *25*, 2767–2775. [CrossRef] [PubMed]

39. Huch, M.; Koo, B.-K. Modeling mouse and human development using organoid cultures. *Development* **2015**, *142*, 3113–3125. [CrossRef]

40. Miyabayashi, K.; Baker, L.A.; Deschenes, A.; Traub, B.; Caligiuri, G.; Plenker, D.; Alagesan, B.; Belleau, P.; Li, S.; Kendall, J.; et al. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. *Cancer Discov.* **2020**, *10*, 1566–1589. [CrossRef]

41. Drost, J.; Clevers, H. Organoids in cancer research. *Nat. Rev. Cancer* **2018**, *18*, 407–418. [CrossRef] [PubMed]

42. Bartfeld, S.; Bayram, T.; van de Wetering, M.; Huch, M.; Begthel, H.; Kujala, P.; Vries, R.; Peters, P.; Clevers, H. In Vitro Expansion of Human Gastric Epithelial Stem Cells and Their Responses to Bacterial Infection. *Gastroenterology* **2015**, *148*, 126–136.e126. [CrossRef] [PubMed]

43. Seidlitz, T.; Merker, S.R.; Rothe, A.; Zakrzewski, F.; von Neubeck, C.; Grutzmann, K.; Sommer, U.; Schweitzer, C.; Scholch, S.; Uhlemann, H.; et al. Human gastric cancer modelling using organoids. *Gut* **2019**, *68*, 207–217. [CrossRef] [PubMed]

44. Yu, H.H.N.; Siu, H.C.; Law, S.; Ho, S.L.; Yue, S.S.K.; Tsui, W.Y.; Chan, D.; Chan, A.S.; Ma, S.; Lam, K.O.; et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. *Cell Stem Cell* **2018**, *23*, 882–897.e811. [CrossRef] [PubMed]

45. Steele, N.G.; Chakrabarti, J.; Wang, J.; Biesiadz, J.; Holokai, L.; Chang, J.; Nowacki, L.M.; Hawkins, J.; Mahe, M.; Sundaram, N.; et al. An Organoid-Based, Personalized Model of Human Gastric Cancer. *Cell. Mol. Gastroenterol. Hepatol.* **2019**, *7*, 161–184. [CrossRef] [PubMed]

46. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. *Annu. Rev. Med.* **2009**, *60*, 167–179. [CrossRef]

47. Sun, G.-L.; Li, Z.; Wang, W.-Z.; Chen, Z.; Zhang, L.; Li, Q.; Wei, S.; Li, B.-W.; Xu, J.-H.; Chen, L.; et al. miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway. *J. Gastroenterol.* **2018**, *53*, 725–739. [CrossRef]

48. Wu, W.; Yang, Z.; Xiao, X.; An, T.; Li, B.; Ouyang, J.; Li, H.; Wang, C.; Zhang, Y.; Zhang, H.; et al. A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer. *J. Cancer* **2020**, *11*, 3013–3019. [CrossRef]

49. Haag, G.M. OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma. Available online: https://clinicaltrials.gov/ct2/show/NCT03429816 (accessed on 17 January 2022).

50. Boj, S.F.; Hwang, C.-I.; Baker, L.A.; Chio, I.I.C.; Engle, D.D.; Corbo, V.; Jager, M.; Ponz-Sarvise, M.; Tiriac, H.; Spector, M.S.; et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. *Cell* **2015**, *160*, 324–338. [CrossRef] [PubMed]

51. Driehuis, E.; van Hoeck, A.; Moore, K.; Kolders, S.; Francis, H.E.; Gulersonmez, M.C.; Stigter, E.C.A.; Drost, J.; Clevers, H.; et al. Establishment of Patient-Derived Organoids from Endoscopic Biopsies and Surgical Tissues. *Ann. Surg. Oncol.* **2018**, *25*, 12214–12228. [CrossRef] [PubMed]

52. Zhang, T.; Zhang, L.; Fan, S.; Zhang, M.; Fu, H.; Liu, Y.; Yin, X.; Chen, H.; Xie, L.; Zhang, J.; et al. Patient-Derived Gastric Cancer Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. *PLoS ONE* **2015**, *10*, e0134493. [CrossRef]

53. Hernandez, M.C.; Bergquist, J.R.; Leiting, J.L.; Ivanics, T.; Yang, L.; Smoot, R.L.; Nagorney, D.M.; Truty, M.J. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. *J. Gastrointest. Surg.* **2019**, *23*, 818–824. [CrossRef] [PubMed]

54. Hoffman, R.M. Patient-derived orthotopic xenografts: Better mimic of metastasis than subcutaneous xenografts. *Nat. Rev. Cancer* **2015**, *15*, 451–452. [CrossRef] [PubMed]

55. Foygel, K.; Wang, H.; Machtaler, S.; Lutz, A.M.; Chen, R.; Fysz, M.; Lowe, A.W.; Tian, L.; Carrigan, T.; Brentnall, T.A.; et al. Detection of Pancreatic Ductal Adenocarcinoma in Mice by Ultrasound Imaging of Thymocyte Differentiation Antigen 1. *Gastroenterology* **2015**, *145*, 885–894.e883. [CrossRef] [PubMed]

56. Choi, Y.Y.; Lee, J.E.; Kim, H.; Sim, M.H.; Kim, K.-K.; Lee, G.; Kim, H.I.; An, J.Y.; Hyung, W.J.; Kim, C.-B.; et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. *Sci. Rep.* **2016**, *6*, 22172. [CrossRef] [PubMed]
61. Wang, H.; Lu, J.; Tang, J.; Chen, S.; He, K.; Jiang, X.; Jiang, W.; Teng, L. Establishment of patient-derived gastric cancer xenografts: A useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. *BMC Cancer* **2017**, *17*, 191. [CrossRef] [PubMed]

62. Blumer, T.; Fofana, I.; Matter, M.S.; Wang, X.; Montazeri, H.; Calabrese, D.; Coto-Llerena, M.; Boldanova, T.; Nuciforo, S.; Kancherla, V.; et al. Hepatocellular Carcinoma Xenographs Established from Needle Biopsies Preserve the Characteristics of the Originating Tumors. *Hepatol. Commun.* **2019**, *3*, 971–986. [CrossRef] [PubMed]

63. Sun, H.; Cao, S.; Mashl, R.J.; Mo, C.-K.; Zaccaria, S.; Wendl, M.C.; Davies, S.R.; Bailey, M.H.; Primeau, T.M.; Hoog, J.; et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. *Nat. Commun.* **2021**, *12*, 5086. [CrossRef] [PubMed]

64. Cho, S.-Y. Patient-derived xenografts as compatible models for precision oncology. *Lab. Anim. Res.* **2020**, *36*, 14. [CrossRef] [PubMed]

65. Chen, C.; Lin, W.; Huang, Y.; Chen, X.; Wang, H.; Teng, L. The Essential Factors of Establishing Patient-derived Tumor Model. *J. Cancer* **2021**, *12*, 28–37. [CrossRef]

66. Morton, J.J.; Bird, G.H.; Keysar, S.B.; Astling, D.P.; Lyons, T.R.; Anderson, R.T.; Glogowska, M.J.; Estes, P.S.; Eagles, J.R.; Le, P.N.; et al. XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. *Oncogene* **2016**, *35*, 290–300. [CrossRef] [PubMed]

67. Kuwata, T.; Yanagihara, K.; Iino, Y.; Komatsu, T.; Ochiai, A.; Sekine, S.; Taniguchi, H.; Katai, H.; Kinoshita, T.; Ohtsu, A. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts. *Cells* **2019**, *8*, 585. [CrossRef] [PubMed]

68. Zhu, Y.; Tian, T.; Li, Z.; Zang, W.; Wang, L.; Wu, J.; Li, Y.; Dong, B.; Li, Y.; Li, N.; et al. Establishment and characterization of patient-derived xenografted tumor using gastroscopic biopsies in gastric cancer. *Sci. Rep.* **2015**, *5*, 8542. [CrossRef]

69. Chen, Z.; Huang, W.; Tian, T.; Zang, W.; Wang, J.; Liu, Z.; Li, Z.; Lai, Y.; Jiang, Z.; Gao, J.; et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. *J. Hematol. Oncol.* **2018**, *11*, 20. [CrossRef]

70. Wang, X.; Fu, R.; Hu, Y.; Du, H.; Li, S.; Li, Z.; Liu, Y.; Li, Q.; Zhang, L.; Ji, J. EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient-derived xenografts with cetuximab. *Oncol. Rep.* **2017**, *38*, 2387–2393. [CrossRef] [PubMed]

71. Okines, A.F.; Cunningham, D. Trastuzumab in gastric cancer. *Eur. J. Cancer* **2010**, *46*, 1949–1959. [CrossRef] [PubMed]

72. Wang, C.J.; Tong, P.J.; Zhu, M.Y. The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived xenograft model of gastric cancer. *Clin. Transl. Oncol.* **2016**, *18*, 507–514. [CrossRef] [PubMed]

73. Rubio-Viqueira, B.; Jimeno, A.; Cusatis, G.; Zhang, X.; Iacobuzio-Donahue, C.; Karikari, C.; Shi, C.; Danenberg, K.; Danenberg, P.V.; Kuramochi, H.; et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer. *Clin. Cancer Res.* **2006**, *12*, 4652–4661. [CrossRef] [PubMed]

74. Delitto, D.; Pham, K.; Vlada, A.C.; Sarosi, G.A.; Thomas, R.M.; Behrns, K.E.; Liu, C.; Hughes, S.J.; Wallet, S.M.; Trevino, J.G. Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements. *Am. J. Pathol.* **2015**, *185*, 1297–1303. [CrossRef]

75. Jung, J.; Lee, C.H.; Seol, H.S.; Choi, Y.S.; Kim, E.; Lee, E.J.; Rhee, J.-K.; Singh, S.R.; Jun, E.S.; Han, B.; et al. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. *Oncotarget* **2016**, *7*, 62533–62546. [CrossRef]

76. Garcia, P.L.; Council, L.N.; Christein, J.D.; Arnoletti, J.P.; Haslin, M.J.; Gamblin, T.L.; Richardson, J.H.; Bjorndal, M.-A.; Yoon, K.J. Development and Histopathological Characterization of Tumor Models of Pancreatic Ductal Adenocarcinoma. *PLoS ONE* **2013**, *8*, e87183. [CrossRef] [PubMed]

77. Torphy, R.J.; Tignanelli, C.J.; Kamande, J.W.; Moffitt, R.A.; Loeza, S.G.H.; Soper, S.A.; Yeh, J.J. Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma. *PLoS ONE* **2014**, *9*, e89474. [CrossRef]

78. Garett-Laguna, I.; Uson, M.; RajeshKumar, N.V.; Tan, A.C.; De Oliveira, E.; Karikari, C.; Villaroeil, M.C.; Solamon, A.; Taylor, G.; Sharma, R.; et al. Tumor Engraftment in Nude Mice and Enrichment in Stroma-Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. *Clin. Cancer Res.* **2011**, *17*, 5793–5800. [CrossRef] [PubMed]

79. Jimeno, A.; Rubio-Viqueira, B.; RajeshKumar, N.; Chan, A.; Solamon, A.; Hidalgo, M. A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer. *Mol. Cancer Ther.* **2010**, *9*, 311–318. [CrossRef]

80. Miller, A.L.; Fehling, S.C.; Garcia, P.L.; Gamblin, T.L.; Council, L.N.; van Waardenburg, R.C.; Yang, E.S.; Bradner, J.E.; Yoon, K.J. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. *eBioMedicine* **2019**, *44*, 419–430. [CrossRef]

81. Nicolle, R.; Blum, Y.; Marisa, L.; Loncle, C.; Gayet, O.; Moutardier, V.; Turrini, O.; Giovanni, M.; Bian, B.; Bigonnet, M.; et al. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. *Cell Rep.* **2017**, *21*, 2458–2470. [CrossRef] [PubMed]
82. Nicolle, R.; Gayet, O.; Duconseil, P.; Vanbruggen, C.; Roques, J.; Bigonnet, M.; Blum, Y.; Elarouci, N.; Armenoult, L.; Ayadi, M.; et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. *Ann. Oncol.* 2021, 32, 250–260. [CrossRef]

83. Dijkstra, K.K.; Cattaneo, C.M.; Weeber, F.; Chalabi, M.; Van De Haar, J.; Fanchi, L.F.; Slagter, M.; Van Der Velden, D.L.; Kaing, S.; Kelderman, S.; et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. *Cell* 2018, 174, 1586–1598.e12. [CrossRef]

84. Nozaki, K.; Mochizuki, W.; Matsumoto, Y.; Matsumoto, T.; Fukuda, M.; Mizutani, T.; Watanabe, M.; Nakamura, T. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. *J. Gastroenterol.* 2016, 51, 206–213. [CrossRef] [PubMed]

85. Chakrabarti, J.; Holokai, L.; Syu, L.; Steele, N.; Chang, J.; Dlugosz, A.; Zavros, Y. Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment. *Methods Mol. Biol.* 2018, 1817, 157–168. [CrossRef] [PubMed]

86. Ohlund, D.; Handy-Santana, A.; Biffi, G.; Elarouci, N.; Armenoult, L.; Nicolle, R.; Gayet, O.; Duconseil, P.; Vanbrugghe, C.; Roques, J.; Bigonnet, M.; Blum, Y.; Centeno, P. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer* 2018, 18, 335. [CrossRef] [PubMed]

87. Jiang, B.; Zhou, L.; Li, J.; Wang, Y.; Liu, C.; You, L.; Guo, J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin with Two Sides? *Front. Oncol.* 2020, 10, 576399. [CrossRef]

88. Bertaux-Skeirik, N.; Centeno, J.; Feng, R.; Schumacher, M.A.; Shivasani, R.A.; Zavros, Y. Co-culture of Gastric Organoids and Immortalized Stomach Mesenchymal Cells. *Methods Mol. Biol.* 2016, 1422, 23–31. [CrossRef] [PubMed]

89. Cherne, L.D.; Jenkins, B.R.; Huang, S.; Spence, J.R.; Walk, S.T.; Wilking, J.N. Long-term flow through human intestinal organoids with the gut organoid flow chip (GOFlowChip). *Lab Chip* 2019, 19, 3552–3562. [CrossRef] [PubMed]

90. Tsai, S.; McOlash, L.; Palen, K.; Johnson, B.; Duris, C.; Yang, Q.; Dwinell, M.B.; Hunt, B.; Evans, D.B.; Gershan, J.; et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer* 2018, 18, 335. [CrossRef] [PubMed]

91. Park, S.E.; Georgescu, A.; Huh, D. Organoids-on-a-chip. *Science* 2019, 364, 960–965. [CrossRef]

92. Sidar, B.; Jenkins, B.R.; Huang, S.; Spence, J.R.; Walk, S.T.; Wilking, J.N. Long-term flow through human intestinal organoids with the gut organoid flow chip (GOFlowChip). *Lab Chip* 2019, 19, 3552–3562. [CrossRef] [PubMed]

93. Sides? *Front. Oncol.* 2020, 10, 6477–6489. [CrossRef]

94. Joo, S.-Y.; Choi, B.-K.; Kang, M.J.; Jung, D.Y.; Park, K.S.; Park, J.B.; Choi, G.S.; Joh, J.-W.; Kwon, C.H.D.; Jung, G.O. et al. Development of functional human immune system with the transplantations of human fetal liver/thymus tissues and expanded hematopoietic stem cells in RAG2−/−γc−/−MICE. *Transplant. Proc.* 2009, 41, 1885–1890. [CrossRef] [PubMed]

95. Kim, M.; Choi, B.; Kim, S.Y.; Yang, J.-H.; Roh, C.R.; Lee, K.-Y.; Kim, S.J. Co-transplantation of fetal bone tissue facilitates the development and reconstitution in human B cells in humanized NOD/SCID/IL-2Rgamma null (NSG) mice. *J. Clin. Immunol.* 2011, 31, 699–709. [CrossRef] [PubMed]

96. Shultz, L.D.; Lyons, B.L.; Burzenski, L.M.; Gott, B.; Chen, X.; Chaleff, S.; Kotb, M.; Gillies, S.D.; King, M.; Mangada, J.; et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mouse null engrafted with mobilized human hematopoietic stem cells. *J. Immunol.* 2005, 174, 6477–6489. [CrossRef] [PubMed]

97. Morten, J.J.; Bird, G.; Refaeli, Y.; Jimeno, A. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. *Cancer Res.* 2016, 76, 6153–6158. [CrossRef] [PubMed]

98. Mao, J.-X.; Wang, J.-Y.; Li, H.-Z.; Guo, H.-R.; Dunmall, L.S.C.; Zhang, Z.-X.; Cheng, Z.-G.; Gao, D.-L.; Dong, J.-Z.; Wang, Z.-D.; et al. Promising xenograft animal model recapitulating the features of human pancreatic cancer. *World J. Gastroenterol.* 2020, 26, 4802–4816. [CrossRef] [PubMed]

99. Zhou, Q.; Facciponte, J.; Jin, M.; Shen, Q.; Lin, Q. Humanized NOD-SCID IL2rg−/− mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. *Cancer Lett.* 2014, 344, 13–19. [CrossRef]

100. Rios-Doria, J.; Stevens, C.; Maddage, C.; Lasky, K.; Koblish, H.K. Characterization of human cancer xenografts in humanized mice. *J. Immunother.* 2020, 8, e000416. [CrossRef] [PubMed]

101. Sannamed, M.F.; Rodríguez, I.; Schalper, K.A.; ONate, C.; Azpilikueta, A.; Rodriguez-Ruiz, M.E.; Morales-Kastreana, A.; Labiano, S.; Perez-Gracia, J.L.; Martin-Algarra, S.; et al. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rgamma null Immunodeficient Mice. *Cancer Res.* 2015, 75, 3466–3478. [CrossRef] [PubMed]

102. Ames, E.; Canter, R.J.; Grossenbacher, S.K.; Mac, S.; Chen, M.; Smith, R.C.; Hagino, T.; Perez-Cunningham, J.; Sckisel, G.D.; Urayama, S.; et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. *J. Immunol.* 2015, 195, 4010–4019. [CrossRef]

103. Zhang, F.; Wang, W.; Long, Y.; Liu, H.; Cheng, J.; Gao, L.; Li, R.; Meng, C.; Yu, S.; Zhao, Q.; et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. *Cancer Commun.* 2018, 38, 60. [CrossRef]
104. Ge, Y.; Zhang, X.; Liang, W.; Tang, C.; Gu, D.; Shi, J.; Wei, X. OncoVee-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients with Synchronous Liver Metastases: A Retrospective Cohort Analysis. *Front. Oncol.* **2021**, *11*, 757383. [CrossRef]  
105. Zhu, X.; Zhu, Y.; Chen, N.; Tang, C.; Shi, J. The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer. *J. Oncol. Pharm. Pract.* **2022**, *in press*. [CrossRef] [PubMed]  
106. Nollmann, F.I.; Ruess, D.A. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? *Biomedicines* **2020**, *8*, 281. [CrossRef] [PubMed]  
107. Grossman, J.E.; Muthuswamy, L.; Huang, L.; Akshinthala, D.; Perea, S.; Gonzalez, R.S.; Tsai, L.L.; Cohen, J.; Bockorny, B.; Bullock, A.J.; et al. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. *Clin. Cancer Res.* **2022**, *28*, 708–718. [CrossRef] [PubMed]